Novo reports stronger CagriSema weight-loss results in post-study analysis of women
Novo reported post-study analyses of its late-stage CagriSema trial showing average weight loss of 25% after 68 weeks among roughly 2,300 women with obesity or overweight, versus about 3% with placebo. The company said the calculation assumed patients stayed…
